Bergen Washburn
About Bergen Washburn
Bergen Washburn is a Scientist II specializing in Toxicology at Entrada Therapeutics, with a background in preclinical safety evaluation and nonclinical development. He has extensive experience in regulatory submissions and conducting nonclinical studies, and he holds a B.S. in Biochemistry from Northeastern University.
Current Role at Entrada Therapeutics
Bergen Washburn currently serves as Scientist II in Toxicology at Entrada Therapeutics, a position held since 2022. In this role, he is involved in various aspects of toxicology research, focusing on the safety evaluation of therapeutic candidates. He collaborates with study directors, principal investigators, and other scientists, representing the toxicology department on multiple program teams. His work emphasizes a patient-centered approach, highlighting the importance of research in improving patient outcomes.
Previous Experience at Acceleron Pharma
Bergen Washburn has extensive experience at Acceleron Pharma, where he worked in various capacities from 2009 to 2022. His roles included Research Associate I and II in Preclinical Safety Evaluation, Associate Scientist I and II in Nonclinical Development, and Research Associate in Formulations/Analytical Development. During his tenure, he prepared nonclinical documents for regulatory submissions and conducted scientific audits at contract research organizations (CROs). His experience encompasses planning and conducting nonclinical studies, including general toxicology and safety pharmacology.
Early Career at WR Grace
Bergen Washburn began his career as a Research Assistant at WR Grace in 2008, where he worked for six months in Cambridge, Massachusetts. This early experience contributed to his foundational knowledge in research methodologies and laboratory practices, setting the stage for his subsequent roles in the pharmaceutical industry.
Educational Background in Biochemistry
Bergen Washburn earned a Bachelor of Science degree in Biochemistry from Northeastern University, completing his studies from 2005 to 2010. This educational background provided him with a strong foundation in biochemical principles, which he applies in his current and previous roles in toxicology and drug development.
Expertise in Nonclinical Studies
Bergen Washburn possesses extensive expertise in planning and conducting both non-GLP and GLP studies. His experience includes general toxicology, developmental and reproductive toxicity (DART), juvenile studies, and safety pharmacology. He regularly prepares essential nonclinical documents for regulatory submissions, including IND, CTA, IB, BLA, and DSUR, demonstrating his proficiency in navigating the regulatory landscape in drug development.